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Sclerosing Hemangioma is a rare lung tumor with polymorphic histologic features that usually occurs in
middle aged women. Based on many immunohistochemical and ultrastructural studies, it is most
probably derived from undifferentiated respiratory epithelial cells. Symptoms are usually due to
enlargement of the tumor and compression of the surrounding tissues. Occurrence of multiple lesions or
metastasis is extremely rare although some authors consider sclerosing hemangioma as a potentially low
grade malignancy tumor. It usually presents with low to moderate uptake on FDG PET imaging. We
present a case of sclerosing hemangioma with strong FDG avidity on PET scan in a 41 year old lady with
history of haemoptysis. A full review of the literature on this topic was performed.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sclerosing hemangioma (SH) of the lung represents a rare
neoplasm that usually occurs in middle-aged womenwith only few
case reports in young adults and children. SH has four major his-
tological patterns, which vary in their proportions: solid, papillary,
sclerotic and haemangiomatous [1]. Occurrence of multiple lesions
ormetastasis is extremely rare [2,3]. Various immunohistochemical
and ultrastructural studies, suggest that SH is most probably arising
from a type II pneumocyte [4]. Because of this, it is also called
“pneumocytoma”.
2. Case history
A 41 year old lady working as a designer was presented to our
outpatient Clinic complaining of cough for several months associ-
ated with episodes of mild haemoptysis. There was no signiﬁcant
previous medical history. Examination of the chest revealedSurgery University College
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Ltd. This is an open access article udecreased breath sound on the right upper lobe. Chest x-ray was
performed and revealed a homogenous mass on the right upper
lobewith no evidence of effusion or pneumothorax. Blood tests and
tumor markers including carcinoembryonic antigen, CA 199 CA 125
and SCC antigen were all normal. A whole body FDG-CT-PET scan
showed in themedial right upper zone, a 3.3 cmwell circumscribed
mass with almost homogenous increased focal uptake (SUV max
8.9). Mild focal activity at a small adjacent right lower paratracheal
node at the tracheobronchial angle, as well as in the right hilum
(SUVmax up to 2.0). No further suspicious for focal avid pulmonary
or pleural abnormality. Lung function tests showed a FEV1 of 2.58
(88% of predicted) with a KCO of 1,40 (82% of predicted). Intra-
operative, the lesion was found in the apical segment of the right
upper lobe. Decision was made to perform an apico-posterior
segmentectomy followed by systematic mediastinal lymphade-
nectomy. The procedure was uncomplicated. Postoperative course
was unremarkable and the patient was discharged home on the
2nd postoperative day. Gross pathological examination revealed a
well circumscribed non encapsulated intrapulmonary tumor
measuring 35  28  22 mm, compressing but not inﬁltrating the
adjacent lung parenchyma and not abutting the pleura. On micro-
scopic examination the lesion showed a variegated appearance
with papillaroid, sclerotic, solid and angiomatoid areas (Fig. 1aee).
The cells lining the papillaroid and angiomatoid areas have a
cuboidal appearance with moderate amount of pale eosinophilic
cytoplasm and round nuclei with inconspicuous nucleoli. Thesender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Sclerosing Pneumocytoma (H&E). Well circumscribed non encapsulated intrapulmonary tumour compressing the adjacent lung parenchyma, showing papillaroid, sclerotic,
solid and angiomatoid areas. There are no areas of necrosis. (a) Sclerosing pneomocytoma (H&E X12.5 Magniﬁcation) Well circumscribed unencapsulated haemorrhagic intra-
sclerosing mass. (b) Sclerosing pneumocytoma (H&E X100 Magniﬁcation) Sclerotic and papillaroid areas. (c) Sclerosing pneumocytoma (H&E X100 Magniﬁcation) Hypercellular
areas. (d) Sclerosing pneumocytoma (H&E X100 Magniﬁcation) Angiomatoid and haemorrhagic areas. (e) Sclerosing pneumocytoma (H&E X200 Magniﬁcation) Papillaroid areas.
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second cell population is observed in the intervening stroma. The
latter have a round uniform cellular morphology with clear cyto-
plasm, distinct cell border and centrally placed small nuclei with
ﬁne chromatin and inconspicuous nucleoli. These cells express
EMA and TTF-1 but not AE1/AE3. None of the cells express CD31 or
CD34 (Fig. 2d). Both cell population are negative for HHV8, CD56,
CD10, Synaptophysin, Melan A, S100, HMB45 and SMA. No mitotic
ﬁgures are observed and the mib-1 proliferation index is less than
1% (Fig. 2e). Several foci of haemosiderosis are observed. There are
no foci of necrosis. Lymph nodes showed reactive lymphoid hy-
perplasia with no evidence of malignancy.
3. Discussion
Sclerosing haemangioma (SH) is a rare benign primary pulmo-
nary tumor. The term sclerosing haemangioma was ﬁrstly intro-
duced by Liebow and Hubbell in 1956 [5] owing to prominent
sclerotization and vascularization of the tissue. Clinically SH pre-
sents most frequently in females (male to female ratio is 1:8) with
higher incidence in the far East [4]. It is presenting as an incidental,
asymptomatic, solitary peripheral coin lesion detected by chest
radiograph [6]. Common symptoms of SH include haemoptysis,
chronic cough, chest pain, expectoration and fever; symptoms are
usually due to enlargement of the tumor and compression of thesurrounding tissue [7]. Tumors range in size from 0.3 to 8 cm and
are most commonly located at the periphery of lung parenchyma;
rarely, the presentation may be bilateral or as an intramediastinal
or endobronchial polypoid mass [8e12]. The FDG-PET scan has
been used to differentiate malignant from benign pulmonary
lesion: SH usually shows low to moderate FDG uptake, which cor-
responds to its slowgrowing behaviour. However the degree of FDG
uptake may vary. Some SH have moderate FDG uptake which may
exceed the cut off value to determine malignant tumors [13].
Usually larger SH (more than 3 cm) may have higher FDG uptake,
whereas smaller SH (less than 3 cm) show lower FDG uptake. The
mechanism of this enhanced uptake of FDG is unknown: benign
and slow growing tumors usually showed low glucose metabolism.
However some larger SH have enhanced FDG uptake, even though
mitotic ﬁgures are rarely seen. Reason for this increased uptake
may be themore active cell proliferation in these larger SH; or these
larger SH may have more cell components which are responsible
for higher FDG uptake. Therefore, larger SH can be misreading as a
malignant neoplasm. The tumor is composed of 2 distinct cellular
components, the round or polygonal or stroma cells and the
cuboidal or surface cells. Variable cystic spaces, ﬁlled with blood
cells, simulating large vascular spaces are seen. Area of sclerosis
may predominate a tumor. Mitotic activity is typically rare [14].
Differential diagnosis of SH include hamartoma, cavernous hae-
mangioma, inﬂammatory lesions, arteriovenous malformations,
Fig. 2. Sclerosing Pneumocytoma (Immunohistochemistry). AE1/AE3 highlights the presence of a rim of cells lining the angiomatoid and papillaroid areas and a second population
of cells found in the intervening spaces which are AE1/AE3 negative. Both cellular components express EMA and TTF-1. (a) Sclerosing Pneumocytoma AE1/AE X100 Magniﬁcation.
(b) Sclerosing Pneumocytoma EMA X100 Magniﬁcation. (c) Sclerosing Pneumocytoma TTF-1100 magniﬁcation. (d) Sclerosing Pneumocytoma CD34100 Magniﬁcation. (e)
Sclerosing Pneumocytoma Mib-1100 Magniﬁcation.
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in the cytological differential diagnosis of SH is well differentiated
adenocarcinoma. Immunocytochemistry can aid in distinguishing
SH from adenocarcinoma because cells are often negative for ker-
atin. The frequent occurrence of SH in young and middle aged
women and the imaging appearance of well circumscribe mass, not
common for adenocarcinoma, can be helpful; sometimes calciﬁ-
cation is observed: this feature more implies benign than malig-
nant entity Another potential differential diagnosis to consider is
well differentiated neuroendocrine carcinoma that shows well
deﬁned, hypervascular, and somewhat calciﬁed lesions [15]. In or-
der to better understand the nature of this lesion numerous studies
have investigated the immunoproﬁle of SH [16e19]: both round
cells and surface cells have been shown to express EMA and TTF-1.
They are negative for factor VIII, S100, smooth muscle actin, cal-
retin, cytokeratin 5/6 and neuroendocrine markers, namely, syn-
aptophysin and chromogranin. The histogenesis of SH has been a
matter of controversy since it was originally described. Although an
epithelial differentiation for this tumor was postulated by several
studies [20,21] other investigators proposed endothelial [10],
mesothelial [22], mesenchymal [23], and neuroendocrine [24] or-
igins for this tumor. The clinical features are usually benign and the
prognosis after surgical excision is usually excellent. However,
some authors consider SH as a potentially low grade malignancy
since a few cases of lymph node metastastases have been reported
[7]; the ﬁrst case of SH with lymph node involvement wasdescribed by Tanaka and coll. in 1986 [25]. In conclusion SH rep-
resents a rare benign pulmonary tumor with signiﬁcant female
predilection. Although considered to be “of uncertain histogenesis”
for decades, there is abundant evidence supporting its epithelial
derivation and it histogenesis from undifferentiated respiratory
epithelium. Its current name, the same term described originally in
1956, is obviously a mismomer. Several names have been proposed,
namely “papillary pneumocytoma” [21], “benign sclerosing pneu-
mocytoma” [8], and “sclerotic haemorrhagic alveolar cell tumor of
the lung” [26]. Morphologically, SH demonstrates a variety of
different patterns. Biologically although capable of metastasis, it
has an indolent behaviour with no reported mortality in the
literature.4. Consent
Written informed consent was obtained from the patient for
publications of this case report and any accompanying images. A
copy of the written consent is available for review by the Editor-in-
Chief of this Journal.Conﬂicts of interest
The authors declare that there is no conﬂict of interest regarding
the publication of this paper.
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